Sancilio Pharmaceuticals announced that it has received the European Medicines Agency’s Orphan Designation for its SC411 (which it plans to market as Altemia), a proposed treatment for sickle cell disease in pediatric patients, in the European Union. The FDA granted the proposed drug a similar designation—the Rare Pediatric Disease designation—in 2017.
Sancilio Pharmaceuticals announced that it has received the European Medicines Agency’s (EMA) Orphan Designation for its SC411 (which it plans to market as Altemia), a proposed treatment for sickle cell disease (SCD) in pediatric patients, in the European Union (EU). The FDA granted the proposed drug a similar designation—the Rare Pediatric Disease designation—in 2017.
“The pediatric population of sickle cell disease patients needs, and deserves, more therapeutic options, and we are excited about the opportunity to gain advice from the European Commission on advancing Altemia in the EU markets,” said Geoffrey Glass, CEO of Sancilio, in a statement.
SCD, a group of rare genetic disorders, is present in approximately 0.6% of the African American population in the United States and affects approximately 1 in every 300 to 500 African American newborns. SCD is caused by mutations in the hemoglobin beta gene, which result in dysfunctional hemoglobin and a depletion of certain lipids in the walls of blood cells. This depletion can lead to occlusion of blood vessels, organ damage, and stroke in children.
Sancilio’s proposed product consists of a mixture of lipids, delivered via a small, soft gelatin capsule intended to be administered once daily, to replenish the lipids destroyed by dysfunctional hemoglobin. The drug maker says that SC411 may treat SCD by decreasing blood cell adhesion, chronic inflammation, and red blood cell hemolysis, which in turn may also reduce the severe pain associated with SCD.
In November 2017, the company reported positive topline results for the drug in a phase 2, randomized, placebo-controlled trial in pediatric patients. The company said that the trial, comprising 68 patients with SCD, aged 5 years to 17 years, met its primary endpoint of change from baseline compared with placebo in blood cell membranes’ fatty acids concentration, and that statistical significance was demonstrated within 3 weeks of treatment. Within 8 weeks, statistically significant improvements in markers of coagulation, inflammation, and adhesions were observed, as was a reduction in crises related to vein occlusion. No serious adverse events were reported during the study.
Overall, 94% of the enrolled patients completed the study, and Sancilio says that “the majority” have opted to participate in the open-label extension that will continue to monitor the drug’s safety and effectiveness.
SC411, if eventually approved, could represent an important treatment option for pediatric patients with SCD; current therapies include blood transfusions, stem cell transplants, and hydroxyurea, a drug that helps to stimulate the production of fetal hemoglobin. In addition, in July 2017, the FDA approved L-glutamine (Endari) for the treatment of patients with SCD aged 5 years or older. While the mechanism of action of L-glutamine in treating SCD is not understood, clinical trials demonstrated that patients receiving the therapy had fewer painful crises compared with patients who received placebo.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen